The impact of functional delayed graft function in the modern era of kidney transplantation - A retrospective study.

delayed graft function dialysis delayed graft function functional delayed graft function graft survival kidney transplantation recipient survival

Journal

Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516

Informations de publication

Date de publication:
01 2021
Historique:
received: 24 05 2020
revised: 10 06 2020
accepted: 27 10 2020
pubmed: 2 11 2020
medline: 29 6 2021
entrez: 1 11 2020
Statut: ppublish

Résumé

The dialysis-based definition of Delayed Graft Function (dDGF) is not necessarily objective as it depends on the individual physician's decision. The functional definition of DGF (fDGF, the failure of serum creatinine to decrease by at least 10% daily on 3 consecutive days during the first week post-transplant), may be more sensitive to reflect recovery after the ischemia-reperfusion injury. We retrospectively analyzed both definitions in 253 deceased donor kidney transplant recipients for predicting death-censored graft failure as primary outcome, using eGFR < 25 ml/min/1.73 m

Identifiants

pubmed: 33131120
doi: 10.1111/tri.13781
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-184

Subventions

Organisme : Redes Temáticas De Investigación Cooperativa En Salud, REDINREN
ID : RD16/0009/0023
Organisme : ISCIII-Subdirección General de Evaluación
Organisme : Fondo Europeo de Desarrollo Regional (FEDER)

Informations de copyright

© 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.

Références

Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814.
Irish WD, Ilsley JN, Schnitzler MA, Feng S, Brennan DC. A Risk Prediction Model for Delayed Graft Function in the Current Era of Deceased Donor Renal Transplantation. Am J Transplant 2010; 10: 2279.
Grosso G, Corona D, Mistretta A, et al. Delayed Graft Function and Long-Term Outcome in Kidney Transplantation. Transplant Proc 2012; 44: 1879.
Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
Yarlagadda SG, Coca SG, Formica RN, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2008; 24: 1039.
Redfield RR, Scalea JR, Zens TJ, et al. Predictors and outcomes of delayed graft function after living-donor kidney transplantation. Transpl Int 2016; 29: 81.
Akkina SK, Connaire JJ, Israni AK, Snyder JJ, Matas AJ, Kasiske BL. Similar Outcomes with Different Rates of Delayed Graft Function May Reflect Center Practice, Not Center Performance. Am J Transplant 2009; 9: 1460.
Moore J, Shabir S, Chand S, et al. Assessing and Comparing Rival Definitions of Delayed Renal Allograft Function for Predicting Subsequent Graft Failure. Transplantation 2010; 90: 1113.
Hall IE, Reese PP, Doshi MD, et al. Delayed Graft Function Phenotypes and 12-Month Kidney Transplant Outcomes. Transplantation 2017; 101: 1913.
Boom H, Mallat MJK, De Fijter JW, Zwinderman AH, Paul LC. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859.
Actividad de donación y trasplante renal España 2019. Organización Nacional de Trasplantes. http://www.ont.es/infesp/Memorias/ActividaddeDonaciónyTrasplanteRenal.pdf. Accessed April 14, 2019.
Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant 2020; 20: 20.
Pascual J, Berger SP, Witzke O, et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol 2018; 29: 1979.
Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation. Am J Transplant 2009; 9: 1876.
Hu X, Zheng J, Li Y, et al. Prediction of kidney transplant outcome based on different DGF definitions in Chinese deceased donation. BMC Nephrol 2019; 20: 409.
Cucchiari D, Ríos J, Molina-Andujar A, et al. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice. J Nephrol 2020; 33: 601.
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 2018; 18: 293.
Johnson RJ, Bradbury LL, Martin K, Neuberger J. Organ donation and transplantation in the UK-The last decade: A report from the UK national transplant registry. Transplantation 2014; 97: S1.
Summers DM, Watson CJE, Pettigrew GJ, et al. Kidney donation after circulatory death (DCD): state of the art. Kidney Int 2015; 88: 241.
Cucchiari D, Molina-Andujar A, Montagud-Marrahi E, et al. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice. Transplantation 2020; 104: 1686.
Nankivell BJ, Ng CHP, O’Connell PJ, Chapman JR. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: Comparison of cyclosporine and tacrolimus eras. Transplantation 2016; 100: 1723.
Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-Month results of the CRAF study. Transplantation 2008; 85: 1261.
Locke JE, Segev DL, Warren DS, Dominici F, Simpkins CE, Montgomery RA. Outcomes of Kidneys from Donors After Cardiac Death: Implications for Allocation and Preservation. Am J Transplant 2007; 7: 1797.

Auteurs

Enrique Montagud-Marrahi (E)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Alícia Molina-Andújar (A)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Jordi Rovira (J)

Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.

Ignacio Revuelta (I)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.
Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.

Pedro Ventura-Aguiar (P)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Gastón Piñeiro (G)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Jessica Ugalde-Altamirano (J)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Francesco Perna (F)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Jose-Vicente Torregrosa (JV)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Federico Oppenheimer (F)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Nuria Esforzado (N)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Frederic Cofán (F)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.

Josep M Campistol (JM)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.
Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Adriana Herrera-Garcia (A)

Pathology Department, Hospital Clínic, Barcelona, Spain.

Jose Ríos (J)

Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain.
Biostatistics Unit, Faculty of Medicine, Universitat Autònoma, Barcelona, Spain.

Fritz Diekmann (F)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.
Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.

David Cucchiari (D)

Nephrology and Renal Transplant Department, Hospital Clínic, Barcelona, Spain.
Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH